Curcumin and pomegrantes - new hope for Alzheimer’s prevention?
New research at University of Warwick will test how curcumin kick-starts the brain’s cleansing of damaging plaques and cells.
New research at the University of Warwick is underway to prove how well curcumin and pomegranates can hack autophagy to prevent Alzheimer’s disease.
The hope is that the studies will show that this naturally-occurring compounds found especially in turmeric can - when combined with intermittent fasting - prevent the build-up of damaging protein fragments that form between nerve cells in the brain and cause neurological problems.
It’s thought that these fragments may be produced as part of the brain’s self-defence process and that their presence is a symptom of the disease. In a healthy brain, these fragments are broken down and eliminated, but problems occur if they begin to accumulate and form the hard, insoluble amyloid plaques known to be one of the major symptoms of Alzheimer's disease.
Previous related research at the Chinese University of Hong Kong in 2008 found that Biocurcumax, a patented extract available as a food supplement, helped prevent further build-up of these amyloid plaques and subsequently was approved by the FDA for investigational Therapy.
The importance of curcumin seems to hinge on its ability to kick-start the cleansing process that otherwise can take up to eighteen hours of fasting for the body to begin by itself. The studies to date have shown that when curcumin is highly ‘bio-available’ - present in the bloodstream in potent amounts for a long-enough period of time – it can help autophagy start much sooner. Biocurcumax is a food supplement designed to allow active curcumin to be retained in the body for more than 8 hours.
Suphil Philipose, of BioTurm, the UK distributor of Biocurcumax says: "Research has already shown that highly bio-available curcumin, when combined with the essential oil of turmeric, can stop the progressive build-up of neurologically-damaging substances. This new research opens up a new world of hope to millions of people.”
Research conducted with the University of Rome in 2015 showed Biocurcumax was able to reverse the dysfunction that sometimes occurs in autophagy, the self-cleansing process.
New studies at the University of Warwick will now seek to show the actual extent to which curcumin and pomegranates can induce autophagy and remove the damaged cells. Should these prove successful, they will progress to a human clinical trial to demonstrate the efficacy of the solution.
Crucially curcumin is thought to also have a positive effect on apoptosis - the normal, controlled death of billions of cells in the adult body every day. Curcumin also restores and maintains a healthy mitochondria, the 'battery unit' of every cell.
Philipose adds: “Nature provides us with curcumin and pomegranates that can be used as hacks to induce and kick start the self-cleansing mechanism in the body. Adjunct to a fasting diet, we may have a pathway for preventing the disease.”
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.